Printer Friendly

INVITRO INTERNATIONAL ANNOUNCES RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDED MARCH 31, 1992

 INVITRO INTERNATIONAL ANNOUNCES RESULTS
 FOR SECOND QUARTER AND SIX MONTHS ENDED MARCH 31, 1992
 IRVINE, Calif., May 18 /PRNewswire/ -- InVitro International (NASDAQ: INVI) announced today results for the second quarter and six months ended March 31, 1992.
 Revenues for the second quarter and six months were $468,603 and $732,739, respectively, as compared to $362,615 and $661,140 for the same periods in 1991. Net losses were $1,296,314 ($.25 per share) and $2,157,609 ($.42 per share), respectively, as compared to $17,053 ($.01 per share) and $1,097 last year. Weighted number of average shares outstanding for the current periods were 5,111,716 and 5,099,812, respectively, as compared to 2,635,457 for both periods last year. In May of 1991, the company completed a public offering of 1,700,000 Units, consisting of an equal number of common stock and redeemable warrants.
 The company noted that sales reported of $468,603 for the second quarter represent a 77 percent increase over the $264,136 in sales for the first quarter ended Dec. 31, 1991. The loss of $1,296,314, as compared to $861,195 in the first quarter, is primarily attributable to increased selling expenses associated with the reorganization and expansion of selling and marketing programs for its in vitro product lines.
 Since reacquiring all marketing rights from its former distributor as of Oct. 1, 1991, the company has incurred approximately $1,588,000 in sales and marketing expenses as a commitment to strengthen its leadership position in the sale and distribution of in vitro safety testing products.
 InVitro International produces and markets proprietary tests to evaluate potential toxicity to humans posed by a wide variety of chemicals and compounds. The company's tests provide a cost-effective, rapid and consistent laboratory alternative to conventional animal testing, enabling manufacturers to screen product formulations to assess the safety of household, consumer and industrial products.
 INVITRO INTERNATIONAL
 Six Months Ended March 31,
 1991 1992
 Revenues $661,140 $732,739
 Costs and expenses 662,237 2,890,348
 Net income (loss) ($1,097) ($2,157,609)
 Income (loss) per share of
 common stock $.00 ($.42)
 Weighted average shares
 outstanding 2,635,457 5,099,812
 Three Months Ended March 31,
 1991 1992
 Revenues $362,615 $468,603
 Costs and expenses 379,668 1,764,917
 Net income (loss) ($17,053) ($1,296,314)
 Income (loss) per share of
 common stock ($.01) ($.25)
 Weighted average shares
 outstanding 2,635,457 5,111,716
 -0- 5/18/92
 /CONTACT: Fran Daniels of Financial Sciences of America, 310-278-4413, for InVitro International/
 (INVI) CO: InVitro International ST: California IN: MTC SU: ERN


ML -- NYON1 -- 1141 05/18/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 18, 1992
Words:453
Previous Article:BEYOND APPOINTS MICHAEL ALLEN TO VICE PRESIDENT OF NORTH AMERICAN SALES
Next Article:INTERTEL COMMUNICATIONS ANNOUNCES RECORD SECOND QUARTER REVENUES, TOP MANAGEMENT CHANGES
Topics:


Related Articles
BONSO ELECTRONICS INTERNATIONAL INC. ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 77%, EARNINGS PER SHARE JUMPS 116%
INVITRO INTERNATIONAL REPORTS SECOND QUARTER RESULTS
InVitro International Reports First Quarter Results
InVitro International Signs Merger Letter of Intent
InVitro International Reports Second Quarter Results
InVitro International Reports Second Quarter Results and Comments on Annual Meeting: Company Looks Forward with Cautious Optimism
InVitro International Reports Second Quarter Profits and 6th Consecutive Quarter of Increased Sales and Cash.
InVitro International Announces Symbol Change.
InVitro International Reports 1st Half 2000 Operating Income on Increased Sales; U. S. Government Agency Approvals Expected to Brighten Future.
InVitro International's 1st Half FY 2001 Produces Net Profit vs. Prior Year Loss.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters